Indo US Bio-Tech Limited
Indo US Bio-Tech Limited Fundamental Analysis
Indo US Bio-Tech Limited (INDOUS.BO) shows moderate financial fundamentals with a PE ratio of 18.46, profit margin of 12.59%, and ROE of 18.90%. The company generates $1.2B in annual revenue with strong year-over-year growth of 42.56%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 75.2/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze INDOUS.BO's fundamental strength across five key dimensions:
Efficiency Score
ExcellentINDOUS.BO demonstrates superior asset utilization.
Valuation Score
ExcellentINDOUS.BO trades at attractive valuation levels.
Growth Score
ExcellentINDOUS.BO delivers strong and consistent growth momentum.
Financial Health Score
ExcellentINDOUS.BO maintains a strong and stable balance sheet.
Profitability Score
WeakINDOUS.BO struggles to sustain strong margins.
Key Financial Metrics
Is INDOUS.BO Expensive or Cheap?
P/E Ratio
INDOUS.BO trades at 18.46 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, INDOUS.BO's PEG of -1.51 indicates potential undervaluation.
Price to Book
The market values Indo US Bio-Tech Limited at 3.16 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 13.33 times EBITDA. This signals the market has high growth expectations.
How Well Does INDOUS.BO Make Money?
Net Profit Margin
For every $100 in sales, Indo US Bio-Tech Limited keeps $12.59 as profit after all expenses.
Operating Margin
Core operations generate 14.57 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $18.90 in profit for every $100 of shareholder equity.
ROA
Indo US Bio-Tech Limited generates $12.66 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Indo US Bio-Tech Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Indo US Bio-Tech Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
INDOUS.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
18.46
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.51
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.16
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.32
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.32
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.67
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.19
vs 25 benchmark
ROA
Return on assets percentage
0.13
vs 25 benchmark
ROCE
Return on capital employed
0.19
vs 25 benchmark
How INDOUS.BO Stacks Against Its Sector Peers
| Metric | INDOUS.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 18.46 | 27.18 | Better (Cheaper) |
| ROE | 18.90% | 860.00% | Weak |
| Net Margin | 12.59% | -121084.00% (disorted) | Strong |
| Debt/Equity | 0.32 | 0.41 | Strong (Low Leverage) |
| Current Ratio | 3.67 | 4.81 | Strong Liquidity |
| ROA | 12.66% | -7173.00% (disorted) | Strong |
INDOUS.BO outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Indo US Bio-Tech Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
89.84%
Industry Style: Cyclical, Commodity, Value
High GrowthEPS CAGR
366.53%
Industry Style: Cyclical, Commodity, Value
High GrowthFCF CAGR
222.37%
Industry Style: Cyclical, Commodity, Value
High Growth